## HOUSE BILL 1675

State of Washington 67th Legislature 2022 Regular Session

By Representatives Bateman, Maycumber, Leavitt, Graham, Dolan, Cody, Griffey, and Riccelli

Prefiled 12/20/21. Read first time 01/10/22. Referred to Committee on Health Care & Wellness.

- AN ACT Relating to exempting a manufacturer of certain dialysate and dialysis devices used by home dialysis patients or a manufacturer's agent from the pharmacy practices act and legend drug
- 4 act; and amending RCW 18.64.257 and 69.41.032.
- 5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:
- 6 **Sec. 1.** RCW 18.64.257 and 2013 c 19 s 20 are each amended to read as follows:
- 8 This chapter shall not prevent a medicare-approved dialysis
- 9 center or facility operating a medicare-approved home dialysis
- 10 program, or a manufacturer of commercially available dialysate and
- dialysis devices used by home dialysis patients, or a manufacturer's agent acting on behalf of such manufacturer, from selling,
- delivering, possessing, or dispensing directly to its dialysis
- 14 patients, ((in case or full shelf lots,)) if prescribed by a
- 15 physician licensed under chapter 18.57 or 18.71 RCW, <u>dialysis devices</u>
- 16 <u>and</u> those legend drugs, in case or full shelf lots, determined by the
- 17 commission pursuant to rule.
- 18 Sec. 2. RCW 69.41.032 and 2016 c 148 s 12 are each amended to

19 read as follows:

p. 1 HB 1675

1 This chapter shall not prevent a medicare-approved dialysis center or facility operating a medicare-approved home dialysis 2 program, or a manufacturer of commercially available dialysate used 3 by home dialysis patients, or a manufacturer's agent acting on behalf 4 of such manufacturer, from selling, delivering, possessing, or 5 6 dispensing directly to its dialysis patients, in case or full shelf lots, if prescribed by a physician licensed under chapter 18.57 or 7 18.71 RCW, those legend drugs determined by the commission pursuant 8 9 to rule.

--- END ---

p. 2 HB 1675